asactal 160 mg gyomornedv-ellenálló tabletta
actavis group ptc ehf. - acetilszalicilsav -
aspaxa 81 mg/20 mg kemény kapszula
astrazeneca kft. - acetilszalicilsav; hilti -
aspirin plus c forte 800 mg/480 mg pezsgőtabletta
bayer hungária kft. - acetilszalicilsav; aszkorbinsav -
bisoblock plus 5 mg/100 mg kemény kapszula
actavis group ptc ehf. - acetilszalicilsav; bizoprolol -
bisoblock plus 5 mg/75 mg kemény kapszula
actavis group ptc ehf. - acetilszalicilsav; bizoprolol -
bisoblock plus 10 mg/100 mg kemény kapszula
actavis group ptc ehf. - acetilszalicilsav; bizoprolol -
bisoblock plus 10 mg/75 mg kemény kapszula
actavis group ptc ehf. - acetilszalicilsav; bizoprolol -
bisoprolol/asa sandoz 10 mg/100 mg kemény kapszula
sandoz hungária kft. - acetilszalicilsav; bizoprolol-fumarát -
plavix
sanofi winthrop industrie - clopidogrel hidrogén-szulfát - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - antitrombotikus szerek - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. megelőzés, a atherothrombotic, valamint thromboemboliás események pitvari fibrillationin felnőtt betegek pitvarfibrilláció, akik legalább egy kockázati tényező a vascularis események, vagy nem megfelelő kezelés a k-vitamin antagonisták, akik egy alacsony vérzés kockázatát, a clopidogrel javasolt kombinálva asa a megelőzés, a atherothrombotic, valamint thromboemboliás események, beleértve a stroke.
lumbinon gél
lichtenstein pharmazeutica gmbh - hidroxietil szalicilát - preparations with salicylic acid derivatives